Working… Menu

Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00395707
Recruitment Status : Completed
First Posted : November 3, 2006
Last Update Posted : February 9, 2009
Genentech, Inc.
Information provided by:
The National Retina Institute

Brief Summary:
The primary objective of this study is to determine the safety & efficacy of ranibizumab for the treatment of retinal angiomatous proliferation secondary to age related macular degeneration.

Condition or disease Intervention/treatment Phase
Macular Degeneration Drug: Lucentis Drug: Ranibizumab Drug: Ranibizumab (Lucentis) Phase 1 Phase 2

Detailed Description:
This study will be a phase I/II open label interventional case series. Twenty patients with retinal angiomatous proliferation will be randomized to receive intravitreal ranibizumab at a dose of 0.3mg/0.05 ml or 0.5mg/0.05 ml. Patients will receive ranibizumab via a pars plana injection on a monthly basis for a total duration of therapy of 12 months. Patients will be followed for a complete 12-month treatment course.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Phase I Study Of Intravitreal Ranibizumab (Lucentis) For The Treatment Of Stage 1 And 2 Retinal Angiomatous Proliferations
Study Start Date : August 2005
Actual Primary Completion Date : April 2008
Actual Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Arm Intervention/treatment
Active Comparator: 1
Lucentis 0.3mg/0.05 ml
Drug: Lucentis
0.3mg/0.05 ml or 0.5mg/0.05 ml
Other Name: Ranibizumab

Drug: Ranibizumab
0.3mg/0.05 ml or 0.5mg/0.05 ml
Other Name: Lucentis

Drug: Ranibizumab (Lucentis)
0.3mg/0.05 ml intravitreally
Other Names:
  • Ranibizumab
  • Lucentis

Active Comparator: 2
Lucentis 0.5mg/0.05 ml
Drug: Lucentis
0.3mg/0.05 ml or 0.5mg/0.05 ml
Other Name: Ranibizumab

Drug: Ranibizumab
0.3mg/0.05 ml or 0.5mg/0.05 ml
Other Name: Lucentis

Drug: Ranibizumab (Lucentis)
0.5mg/0.05 ml
Other Names:
  • Ranibizumab
  • Lucentis

Primary Outcome Measures :
  1. Proportion of patients with stabilization of visual acuity, vision loss of < 15 letters [ Time Frame: 2 years ]
  2. Proportion of subjects who gain at least 15 letters in the best corrected visual acuity score at 6 and 12 months compared to baseline [ Time Frame: 12 months ]
  3. Incidence and severity of ocular adverse events [ Time Frame: 12 months ]
  4. Incidence and severity of non-ocular adverse events [ Time Frame: 12 months ]
  5. Changes in vital signs [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Assess the systemic and local safety of ranibizumab (0.3mg or 0.5mg) in patients with RAP lesions [ Time Frame: 12 months ]
  2. Assess the impact of ranibizumab (0.3mg or 0.5mg) on time to improvement in retinal thickness by OCT [ Time Frame: 2 years ]
  3. Assess the impact of ranibizumab (0.3mg or 0.5 mg) on leakage from RAP lesions by Fluorescein angiography [ Time Frame: 2 years ]
  4. Static / high speed ICG appearance to assess the impact of ranibizumab (0.3mg or 0.5mg) on persistence / recurrence of RAP lesion and monitor for development of retinal-choroidal anastomoses [ Time Frame: 2 years ]
  5. Assess the impact of ranibizumab (0.3mg or 0.5mg) on development of retinal-choroidal anastomoses as determined on clinical examination and high speed ICG [ Time Frame: 2 years ]
  6. Assess the impact of ranibizumab (0.3mg or 0.5mg) on development of subretinal fibrosis as determined by clinical examination [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study.
  • Age > 50 years
  • Definite characteristic signs of age related macular degeneration including drusen
  • Presence of retinal angiomatous proliferation as determined by clinical signs (intra retinal hemorrhage, retinal edema, cystic retinal edema) and angiography (occult leakage on fluorescein angiography, hot spot on static ICG, visible RAP lesion of high speed ICG)

Exclusion Criteria:

  • Prior treatment with verteporfin, external-beam radiation therapy, or transpupillary thermotherapy in the study eye (predominantly classic CNV can however only be included if the subject had up to 3 prior PDT treatments)
  • Treatment with verteporfin in the non-study eye less than 7 days preceding Day 0
  • Previous participation in a clinical trial (for either eye) involving anti angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors, etc.)
  • Previous subfoveal focal laser photocoagulation involving the foveal center in the study eye
  • Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding Day 0
  • History of vitrectomy, submacular surgery, or other surgical intervention for AMD in the study eye
  • Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00395707

Layout table for location information
United States, Maryland
National Retina Institute
Chevy Chase, Maryland, United States, 20815
National Retina Institute
Towson, Maryland, United States, 21204
Sponsors and Collaborators
The National Retina Institute
Genentech, Inc.
Layout table for investigator information
Principal Investigator: Thomas M Johnson, MD National Retina Institute

Layout table for additonal information
Responsible Party: T. Mark Johnson, MD, National Retina Institute Identifier: NCT00395707     History of Changes
Other Study ID Numbers: FVF3423s
First Posted: November 3, 2006    Key Record Dates
Last Update Posted: February 9, 2009
Last Verified: February 2009
Keywords provided by The National Retina Institute:
Macular Degeneration
Age Related Macular Degeneration
Retinal Angiomatous Proliferations
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents